This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q22.4 | Special Copayment Reduction: V146 (rare disease special copayment reduction) |
| B. Synonyms | Tricuspid atresia (TA), functional single ventricle |
| C. Adult onset | Possible first onset in adulthood: very low — diagnosed in the neonatal and infant period because of cyanosis or heart failure, and patients who survive to adulthood after staged Fontan surgery are managed in ACHD clinics. Fontan-related complications (liver disease, protein-losing enteropathy, arrhythmia) sometimes first appear in adulthood. |
| 1. History | 1952 Glenn operation → 1968 Fontan-Baudet operation → TCPC (1988) → standardization of the modern 3-stage Fontan pathway. |
| 2. Causes | Abnormal tricuspid valve development. Edwards-Bargeron classification (type I: normally related great vessels, type II: with TGA, etc.). Mostly sporadic. Pulmonary blood flow depends on VSD, PDA, or BT shunt. |
| 3. Genetics | Mostly sporadic. 22q11.2 deletion, GATA4, and NKX2.5 variants rarely reported. CMA/FISH recommended. |
| 4. General epidemiology | 1~3% of congenital heart disease. The most common form of functional single ventricle. Adult survivors of Fontan surgery are increasing. Korean Q22.4, special copayment reduction V146. |
| 5. Pathophysiology | No right atrium-right ventricle communication → functional single ventricle (left ventricle). Passive pulmonary circulation after Fontan surgery → chronic low cardiac output, elevated central venous pressure, visceral congestion. |
| 6. Symptoms | Insufficient pulmonary blood flow: cyanosis (neonatal period). Excessive pulmonary blood flow: heart failure. After Fontan: exercise intolerance, protein-losing enteropathy, arrhythmia, hepatic congestion. |
| 7. Signs | Cyanosis, clubbing. ECG: left axis deviation, left ventricular hypertrophy (specific pattern of tricuspid atresia). Echocardiography: tricuspid atresia, VSD, great vessel connection. After Fontan: single ventricle function, circuit patency. |
| 8. Screening | Neonatal CCHD oxygen saturation screening. Prenatal fetal echocardiography (ventricular size disproportion on four-chamber view, absent tricuspid valve). Follow-up of atrial defect size. |
| 9. Diagnosis | Echocardiography (tricuspid atresia, Edwards classification, VSD, pulmonary artery). Cardiac MRI (single ventricle function, Fontan circuit). Cardiac catheterization (PVR measurement, indication for Fontan surgery). |
| 10. Treatment | 3 stages: ① neonate (BT shunt/PAB) ② 4~6 months of age (BDG, bidirectional Glenn) ③ 2~4 years of age (Fontan TCPC). After Fontan: anticoagulation, arrhythmia management, treatment of liver and intestinal complications. |
| 11. Prognosis | Fontan 10-year survival 80~90%, 20-year 65~75%. Long-term complications: FALD (liver disease), PLE (protein loss), arrhythmia, thrombus, heart failure. |
| 12. Prevention | Early prenatal diagnosis. CCHD screening. Regular follow-up at an ACHD specialty center after Fontan surgery (liver, single ventricle function, arrhythmia, anticoagulation). |
| 13. References | List of 10 key references |
Tricuspid atresia (TA) is a congenital heart disease in which the tricuspid valve is completely unformed so that there is no communication between the right atrium and right ventricle, with functional single ventricle physiology. Early descriptions of this malformation were made in autopsy studies of the late 19th century, but a clinically systematized understanding came after the mid-20th century.
In 1952, the Glenn operation (superior vena cava-right pulmonary artery shunt) was introduced, making palliative surgery to increase pulmonary blood flow possible in patients with tricuspid atresia. Later, in 1968, Fontan and Baudet performed the first right atrium-pulmonary artery connection (Fontan operation) in patients with tricuspid atresia, establishing an approach to correct functional single ventricle physiology. The Fontan operation was subsequently applied to various single-ventricle congenital heart diseases and became the standard surgical pathway for single-ventricle physiology.
A staged approach is established in the modern era. The 3-stage strategy of ① neonatal and infant palliative surgery (BT shunt or PA banding), ② bidirectional Glenn shunt (BDG: superior vena cava-pulmonary artery connection) at 4~6 months of age, and ③ the Fontan operation (total cavopulmonary connection, TCPC) at 2~4 years of age is now standard. This staged approach is a strategy that maximizes the function of the single-ventricle heart while gradually lowering pulmonary vascular resistance.
Tricuspid atresia arises from abnormal development of the tricuspid valve and right ventricle during the embryonic stage. The tricuspid valve, which normally develops from the atrioventricular endocardial cushion, does not form and is replaced by a fibrous or muscular membrane (muscular plate), blocking the connection between the right atrium and right ventricle.
Tricuspid atresia is classified according to the great vessel connection and associated malformations. According to the Edwards-Bargeron classification: Type I (normally related great vessels, most common 70%): Ia (no VSD, pulmonary atresia), Ib (small VSD, pulmonary stenosis), Ic (large VSD, pulmonary hypertension). Type II (with transposition of the great arteries (TGA), about 30%): IIa, IIb, IIc. Type III (other great vessel anomalies).
Regarding genetic causes, tricuspid atresia mostly occurs sporadically, and cases with an established specific single-gene cause are rare. 22q11.2 deletion, NKX2.5 variants, and other variants in genes related to congenital heart disease are rarely reported. As environmental factors, early-pregnancy diabetes and retinoid exposure are general risk factors.
Tricuspid atresia mostly occurs sporadically, and a specific single-gene cause is not well known. The familial recurrence rate is estimated to be low. However, because cases accompanied by 22q11.2 deletion and other chromosomal abnormalities have been reported, performing chromosomal microarray (CMA) or 22q11.2 FISH testing in all patients is recommended.
Tricuspid atresia rarely accompanies Down syndrome (trisomy 21). De novo variants in cardiac transcription factor genes such as GATA4 and NKX2.5 have been reported in some patients with tricuspid atresia. The frequency of 22q11.2 deletion may be slightly higher in patients with tricuspid atresia accompanied by transposition of the great arteries (TGA). When pregnancy is planned in a patient after Fontan surgery, genetic counseling and fetal echocardiographic surveillance are needed.
Tricuspid atresia accounts for about 1~3% of all congenital heart disease and occurs in about 1 of 8,000~15,000 live births. It is one of the most common forms of functional single-ventricle congenital heart disease. No significant difference by sex has been reported. In Korea it is classified under code Q22.4 and is eligible for special copayment reduction V146.
With advances in the Fontan operation, survival of patients with tricuspid atresia has improved dramatically, and the number of patients surviving to adulthood after Fontan surgery continues to increase. Adult patients after Fontan surgery worldwide are estimated at tens of thousands and make up an important share of ACHD clinics. Managing long-term complications related to the Fontan circulation (Fontan-associated liver disease, protein-losing enteropathy, lymphatic abnormalities, arrhythmia) is the main challenge in these patients.
The core pathophysiology of tricuspid atresia is that there is no communication between the right atrium and right ventricle, so systemic venous blood cannot go directly to the pulmonary artery. Systemic venous blood returns to the systemic circulation via the route of right atrium → atrial-level defect (PFO or ASD) → left atrium → left ventricle → aorta. Pulmonary blood flow goes from the (poorly developed) right ventricle to the pulmonary artery through the VSD, or is supplied through the ductus arteriosus (PDA) or a BT shunt. Thus a functional single-ventricle physiology is established in which the left ventricle supports both the systemic and pulmonary circulations.
Pathophysiology of the Fontan circulation: after Fontan surgery, systemic venous blood flows directly into the pulmonary artery without the help of a ventricular pump (passive pulmonary circulation), so a lower cardiac output than normal is structurally inherent. Low pulmonary blood flow and chronically elevated central venous pressure (CVP) cause chronic congestion of the liver, intestine, and lymphatic system. Fontan-related complications (Fontan-associated liver disease, protein-losing enteropathy, Fontan-related heart failure, arrhythmia) arise from the incompleteness of this passive pulmonary circulation.
The symptoms of tricuspid atresia depend on the amount of pulmonary blood flow. Insufficient pulmonary blood flow (with pulmonary stenosis or atresia): cyanosis is severe from the neonatal period and the patient is ductus-dependent. Excessive pulmonary blood flow (large VSD + normal pulmonary artery, or with TGA): cyanosis is mild, but symptoms of heart failure (tachypnea, feeding difficulty) are the main problem.
Before BDG surgery: after palliative surgery, cyanosis persists to some extent but at a level that allows feeding. After Fontan surgery: cyanosis is markedly reduced or disappears, but exercise intolerance persists because of low cardiac output. Symptoms of Fontan circulation complications: edema, ascites, and hypoalbuminemia in protein-losing enteropathy. Abdominal pain and abdominal distension due to hepatic congestion. Palpitations and syncope with arrhythmia (atrial fibrillation, atrial flutter). Risk of Fontan-related cerebral thrombosis.
Neonatal and infant period: cyanosis, clubbing (when pulmonary blood flow is insufficient), rapid breathing, hepatomegaly (in heart failure). ECG: left axis deviation (Left Axis Deviation) and left ventricular hypertrophy are characteristic (no right ventricular hypertrophy compared with normal). Atrial enlargement findings. Chest X-ray: decreased pulmonary vascular markings (insufficient pulmonary blood flow) or increased (excessive pulmonary blood flow), cardiomegaly (left ventricle predominant). Echocardiography: confirmation of tricuspid atresia, atrial defect size (essential for maintaining the right-to-left shunt), right ventricular size, presence and size of VSD, great vessel connection (Edwards classification). After BDG/Fontan: patency of the Fontan circuit, single ventricle function, presence of pulmonary venous congestion.
Tricuspid atresia is likely to be detected by neonatal CCHD oxygen saturation screening (SpO2 < 95%). In forms with insufficient pulmonary blood flow, SpO2 is very low and it is detected immediately. On prenatal fetal echocardiography (18~22 weeks of gestation), ventricular size disproportion on the four-chamber view and an absent or poorly developed tricuspid valve are diagnostic clues. Because survival requires that the size of the atrial-level defect be maintained, following the atrial defect size is important when diagnosed prenatally.
Echocardiography is central to the diagnosis and anatomical classification (Edwards-Bargeron) of tricuspid atresia. It evaluates tricuspid atresia (muscular or fibrous membrane), size of the atrial defect (whether the right atrium → left atrium shunt is maintained), right ventricular size, presence, size, and location of VSD, great vessel connection (normal or TGA), pulmonary artery size and presence of stenosis, and presence of a ductus arteriosus. Cardiac MRI is useful for evaluating single-ventricle volume and function and the Fontan circuit. Cardiac catheterization is needed for measuring pulmonary vascular resistance (assessing eligibility for Fontan surgery).
Treatment of tricuspid atresia follows a staged Fontan surgical pathway. Stage 1 (neonate to infancy): pulmonary blood flow regulating surgery. For insufficient pulmonary blood flow: a modified BT shunt (subclavian artery-pulmonary artery Gore-Tex conduit) to increase pulmonary blood flow. For excessive pulmonary blood flow: pulmonary artery banding (PAB) to limit pulmonary blood flow and prevent progression of pulmonary hypertension. When the atrial defect is restrictive: balloon atrial septostomy (Rashkind procedure) or surgical atrial septectomy.
Stage 2 (4~6 months of age): bidirectional Glenn shunt (BDG): the superior vena cava (SVC) is anastomosed end-to-side to the right pulmonary artery so that upper-body venous blood flows directly into the lungs. The effect is to lower pulmonary vascular resistance and reduce single-ventricle volume overload.
Stage 3 (2~4 years of age): Fontan operation (Fontan completion, TCPC): the inferior vena cava (IVC) is also connected to the pulmonary artery so that all systemic venous blood flows directly into the lungs. A lateral tunnel or extracardiac conduit method is used. The lower the pulmonary vascular resistance, the better the results of Fontan surgery.
In the prognosis of tricuspid atresia, survival has improved greatly when the staged Fontan pathway is completed successfully. Survival after Fontan surgery is reported at about 80~90% at 10 years and about 65~75% at 20 years. However, long-term complications due to the inherent incompleteness of the Fontan circulation become increasingly serious from adulthood onward.
Fontan-related long-term complications: Fontan-associated liver disease (FALD): hepatic fibrosis, cirrhosis, and risk of hepatocellular carcinoma due to chronic hepatic congestion. Protein-losing enteropathy (PLE): hypoalbuminemia, edema, and ascites due to intestinal lymphatic dysfunction. Fontan circulation failure: decline in single-ventricle function. Thromboembolism: thrombus formation from blood stasis within the Fontan circuit, requiring anticoagulation. Arrhythmia: atrial fibrillation and atrial flutter are common in adults after Fontan surgery and worsen the Fontan circulation.
There is currently no established method for preventing the occurrence of tricuspid atresia. Early diagnosis through prenatal fetal echocardiography and neonatal CCHD screening is the best preventive strategy. With early diagnosis, planning an appropriate surgical pathway (staged Fontan) and maintaining anatomical conditions favorable for Fontan surgery (low pulmonary vascular resistance, adequate single-ventricle function) determine long-term prognosis.
Adult patients after Fontan surgery are regularly evaluated at an ACHD specialty center for liver function (liver ultrasound, AFP, liver MRI), single-ventricle function (cardiac MRI), arrhythmia (Holter, ECG), anticoagulation (warfarin or NOAC), pulmonary vascular resistance (cardiac catheterization), lymphatic abnormalities, and renal function. Strenuous exercise requires individualized guidance because cardiac output is limited in Fontan physiology.
Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax. 1971;26(3):240-248. DOI: 10.1136/thx.26.3.240. PMID: 5089489.
Gewillig M. The Fontan circulation. Heart. 2005;91(6):839-846. DOI: 10.1136/hrt.2004.051789. PMID: 15894787.
de Leval MR, Kilner P, Gewillig M, Bull C. Total cavopulmonary connection: a logical alternative to atriopulmonary connection for complex Fontan operations. J Thorac Cardiovasc Surg. 1988;96(5):682-695. PMID: 3184963.
d'Udekem Y, Iyengar AJ, Cochrane AD, et al. The Fontan procedure: contemporary techniques have improved long-term outcomes. Circulation. 2007;116(11 Suppl):I157-I164. DOI: 10.1161/CIRCULATIONAHA.106.679902. PMID: 17846311.
Khairy P, Fernandes SM, Mayer JE Jr, et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation. 2008;117(1):85-92. DOI: 10.1161/CIRCULATIONAHA.107.738559. PMID: 18071068.
Kwon EN, Meza JM, Beasley GS, et al. Long-term outcomes after tricuspid atresia repair: 50 years of experience at a single center. World J Pediatr Congenit Heart Surg. 2021;12(4):504-511. DOI: 10.1177/21501351211005064. PMID: 33899640.
Rychik J, Atz AM, Celermajer DS, et al. Evaluation and management of the child and adult with Fontan circulation: a scientific statement from the American Heart Association. Circulation. 2019;140(6):e234-e284. DOI: 10.1161/CIR.0000000000000696. PMID: 31256636.
Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease. J Am Coll Cardiol. 2019;73(12):e81-e192. DOI: 10.1016/j.jacc.2018.08.1029. PMID: 30121239.
Varma C, Warr MR, Hendler AL, et al. Prevalence of 'silent' pulmonary emboli in adults after the Fontan operation. J Am Coll Cardiol. 2003;41(12):2252-2258. DOI: 10.1016/S0735-1097(03)00490-4. PMID: 12821257.
Cheung YF, Cheuk DK, Chau AK, Chiu CS. Hepatic and portal venous flow characteristics in patients after total cavopulmonary connection. Ultrasound Med Biol. 2004;30(2):145-150. DOI: 10.1016/j.ultrasmedbio.2003.11.002. PMID: 14998672.